- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.
EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use
EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy
EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
EP: 6.The Patient Journey: Effectively Managing AD Itch Early On
EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care
- When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
- How do treatment options differ in terms of administration schedule (continuous versus non-continuous), and how does the need for breakthrough topical steroids influence your decision on therapy options?
- In the managed care space, what is the role of combination therapy in AD and what restrictions might be considered?
- From a payer’s perspective, how do you take into account when a product does not need continuous use and still be efficacious, potentially allowing for time off therapy?
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
Global Analysis Sheds Light on Women’s Cancer Trends
May 11th 2025As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.
Read More
